
Metatri 35mg Tablet MR
Marketer
Santiago Lifesciences Pvt Ltd
Salt Composition
Trimetazidine (35mg)
Overview Metatri 35mg Tablet MR
Cardoxin 35mg Extended-Release Tablets are prescribed for angina pectoris, a type of chest pain stemming from heart conditions. This medication acts as a preventative measure against angina episodes but is ineffective once an attack begins. It can be administered independently or alongside other cardiac medications. Dosage and frequency of Cardoxin 35mg Extended-Release Tablets should strictly adhere to your physician's instructions, taken consistently with or without food. Your doctor may adjust the prescribed schedule based on your response to treatment. Continuous use, even during symptom-free periods, is crucial for maximizing efficacy and minimizing future cardiac events. Discontinuing treatment may trigger a recurrence of chest pain. Complementing medication with a heart-healthy lifestyle – including smoking cessation, moderate alcohol consumption, a balanced diet, regular physical activity, and stress management – is strongly recommended. Potential side effects, such as nausea, vomiting, abdominal discomfort, diarrhea, headache, dizziness, skin rashes (including hives and itching), and weakness, may occur. Report any persistent or bothersome side effects to your doctor. Prior to commencing treatment, inform your doctor of any pre-existing liver or kidney conditions, pregnancy, breastfeeding, or other concurrent medications you are using.
Uses of Metatri 35mg Tablet MR
Managing chest pain associated with angina pectoris
Major Benefits of Metatri 35mg Tablet MR:
Consume this medication precisely as directed by your physician, adhering to both the prescribed dosage and treatment period. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. The Metatri 35mg Modified-Release Tablet should be administered with a meal.
Common Side effects of Metatri 35mg Tablet MR:
- Dizziness
- Headache
- Nausea
- Vomiting
- Weakness
- Rash
- Abdominal pain
- Indigestion
- Itching
- Diarrhea
- Hives
How to use Metatri 35mg Tablet MR:
Consume this medication precisely as your physician directs, adhering to the prescribed dosage and timeframe. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. The Metatri 35mg Modified-Release Tablet should be taken with a meal.
How Metatri 35mg Tablet MR works:
Metatri 35mg Modified-Release tablets are used to treat angina. They reduce the heart's oxygen demand by altering its metabolic processes, favoring glucose over fats. This improves the heart's overall functionality.
SAFETY ADVICE
AlcoholUNSAFE
Concurrent use of Metatri 35mg Modified-Release tablets and alcohol may result in significant sleepiness.
PregnancyCONSULT YOUR DOCTOR
Data on Metatri 35mg Tablet MR use in pregnancy is lacking. Seek medical advice from your physician.
Breast feedingCONSULT YOUR DOCTOR
Data on the safety of Metatri 35mg Modified-Release tablets while breastfeeding is lacking. Seek medical advice from your physician.
DrivingUNSAFE
Taking a Metatri 35mg Modified-Release tablet may cause drowsiness, blurred vision, or dizziness. Refrain from driving if you experience these effects.
KidneyCAUTION
For individuals with kidney impairment, Metatri 35mg Modified-Release tablets require careful administration and may necessitate dosage modification. Consult your physician for guidance. Metatri 35mg Modified-Release tablets are contraindicated in patients experiencing severe kidney disease.
LiverCONSULT YOUR DOCTOR
Data regarding the use of Metatri 35mg Tablet MR in individuals with hepatic impairment is scarce. Physician consultation is advised.
What if you forget to take Metatri 35mg Tablet MR :
Should you forget a dose of Metatri 35mg Modified-Release Tablet, administer it promptly. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Metatri 35mg Tablet MR
| Label | Value |
|---|---|
| Chemical Type | Benzylamines |
| Developing Habits | No. |
| Treatment Category | HEART |
| Action Class | Fatty acid modifier and sodium channel inhibitor |
